NovaBridge Biosciences (FRA:0VY) Other Current Payables: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0VY NovaBridge Biosciences FRA:0VY
32 GF Score
Price €1.54
! 3 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Other Current Payables?

NovaBridge Biosciences FRA:0VY +0.65% 32 Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

NovaBridge Biosciences's Other Current Payables for the quarter that ended in Dec. 2025 was €0.00 Mil.

NovaBridge Biosciences's quarterly Other Current Payables increased from Jun. 2025 (€0.00 Mil) to Sep. 2025 (€6.13 Mil) but then declined from Sep. 2025 (€6.13 Mil) to Dec. 2025 (€0.00 Mil).

NovaBridge Biosciences Other Current Payables Related Terms

NovaBridge Biosciences Other Current Payables Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences Other Current Payables Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only 7.29 15.79 0.00 0.00 0.00

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 6.13 0.00
FRA:0VY
32GF Score
NovaBridge Biosciences FRA:0VY
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
NovaBridge Biosciences (FRA:0VY) has a Other Current Payables of €0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Other Current Payables too high?
NovaBridge Biosciences' current Other Current Payables is €0.00 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Other Current Payables compare to KROS and SLNCF?
NovaBridge Biosciences' Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current Other Current Payables of €0.00 Mil. The current Other Current Payables is €0.00 Mil. NovaBridge Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
32GF Score

Get the complete analysis for FRA:0VY

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price